Organon Corp - רווח נקי למניה אחת בשנים עשר החודשים האחרונים OGN

Organon & Co. (OGN) specializes in reproductive medicine and biosimilars, maintaining leadership in the contraception segment. The annual growth of basic net income per share (ttm) on the GURU.Markets chart demonstrates capital dynamics, where the value of -58.10 reflects this status. A global network of plants and patents ensures stable production, while a portfolio of mature brands guarantees a steady cash flow.

This indicator measures the rolling year net profit per share dynamics, reflecting cost management efficiency and the business's ability to maintain margins under inflationary pressure. By analyzing the annual EPS growth rate over the last 12 months, investors assess the resilience of Organon & Co. (OGN) as it reallocates funds from legacy drugs toward the development of innovative women's health products.